“The result of ‘hard Brexit’ would not only be a sick economy but sick patients unable to access a cure.”
Being cut off from the European system could put British patients at the back of the queue for new medicines because applications for new licenses from Europe – currently a market of at least 500 million people – would take priority over the much smaller UK market with its population of 65 million.
The latest warning comes amid growing concern that Britain’s successful pharmaceutical and biotechnology sector could be hit hard by the country’s decision to leave the EU, given the international nature of science and science-based industry.
“We face a simple choice: we either participate in full in that global scientific community or we prejudice a key British national interest,” Stephen Dorrell, who served as a health minister under Conservative Prime Minister John Major in the 1990s, wrote in an introduction to the report.
He is one of several Conservatives to criticize Brexit, now being pushed through by a Conservative government.
Britain’s export-orientated drugs industry, which includes global players GlaxoSmithKline and AstraZeneca, is seeking assurances from ministers about its future after last week’s post-Brexit deal with carmaker Nissan.
GlaxoSmithKline Chief Executive Andrew Witty and AstraZeneca CEO Pascal Soriot co-chair a life sciences steering group which will meet ministers on Nov. 23 to outline the priorities of the pharma and biotech industry.
In addition to worries about trade barriers and drug regulation once Britain leaves the EU, industry executives are concerned about their ability to recruit foreign staff and loss of EU science funding.
(Reporting by Ben Hirschler; Editing by Raissa Kasolowsky)
Source: Reuters Health